The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M(pro)) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Xiaojing, Xu, Wei, Liu, Yang, Li, Hua, Chen, Lixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201905/
https://www.ncbi.nlm.nih.gov/pubmed/37244162
http://dx.doi.org/10.1016/j.ejmech.2023.115491
_version_ 1785045346546614272
author Pang, Xiaojing
Xu, Wei
Liu, Yang
Li, Hua
Chen, Lixia
author_facet Pang, Xiaojing
Xu, Wei
Liu, Yang
Li, Hua
Chen, Lixia
author_sort Pang, Xiaojing
collection PubMed
description The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M(pro)) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 M(pro) inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 M(pro) inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 M(pro) and summarizes the research progress of SARS-CoV-2 M(pro) inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.
format Online
Article
Text
id pubmed-10201905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-102019052023-05-22 The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022 Pang, Xiaojing Xu, Wei Liu, Yang Li, Hua Chen, Lixia Eur J Med Chem Review Article The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M(pro)) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 M(pro) inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 M(pro) inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 M(pro) and summarizes the research progress of SARS-CoV-2 M(pro) inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future. Elsevier Masson SAS. 2023-09-05 2023-05-22 /pmc/articles/PMC10201905/ /pubmed/37244162 http://dx.doi.org/10.1016/j.ejmech.2023.115491 Text en © 2023 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Pang, Xiaojing
Xu, Wei
Liu, Yang
Li, Hua
Chen, Lixia
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
title The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
title_full The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
title_fullStr The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
title_full_unstemmed The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
title_short The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
title_sort research progress of sars-cov-2 main protease inhibitors from 2020 to 2022
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201905/
https://www.ncbi.nlm.nih.gov/pubmed/37244162
http://dx.doi.org/10.1016/j.ejmech.2023.115491
work_keys_str_mv AT pangxiaojing theresearchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT xuwei theresearchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT liuyang theresearchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT lihua theresearchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT chenlixia theresearchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT pangxiaojing researchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT xuwei researchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT liuyang researchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT lihua researchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022
AT chenlixia researchprogressofsarscov2mainproteaseinhibitorsfrom2020to2022

Ejemplares similares